Illumina exceeded Q2FY25 expectations and raised FY25 guidance, driven by resilient Chinese operations and strong clinical market growth, especially in oncology. The company is expanding into proteomics with the SomaLogic acquisition and new single-cell CRISPR offerings, aiming for high future revenue growth. Despite ongoing headwinds from China restrictions and US academic funding cuts, Illumi...
Illumina, Inc. (NASDAQ:ILMN ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Ankur Dhingra - Chief Financial Officer Brian Blanchett - VP of Finance & Treasurer and Interim Head of Investor Relations Jacob Thaysen - CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Gregory Brennan...
Explore the exciting world of Illumina (ILMN -3.70%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basis GAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025 GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025 Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025 For fiscal year 2025, we now expect: Total com...
Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input Illumina's growing research and clinical oncology portfolio broadens access to critical biomarker testing SAN DIEGO , July 30, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of the next generation of TruSigh...
With Illumina's divestiture of GRAIL, the company will improve its operating expenses, since GRAIL reported significant losses while it was part of Illumina. The global DNA sequencing market is expected to grow at a CAGR of 9% from 2024 and 2028, which is a positive aspect for Illumina. Illumina has reported higher gross profit margins than its peers, which reflects that its core business is pr...
SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, ...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.